An aptamer-mediated base editing platform for simultaneous knock-in and multiple gene knockout for allogeneic CAR-T cells generation

Gene editing technologies hold promise for enabling the next generation of adoptive cellular therapies. Conventional gene editing platforms that rely on nuclease activity, such as Clustered regularly interspaced short palindromic repeats-CRISPR associated protein 9 (CRISPR-Cas9), allow efficient introduction of genetic modifications; however, these modifications occur via the generation of DNA double-strand breaks (DSBs) and can lead to unwanted genomic alterations and genotoxicity. Here, we apply the novel modular RNA aptamer-mediated Pin-point™ base editing platform to simultaneously introduce multiple gene knockouts and site-specific integration of a transgene in human primary T cells. We demonstrate high editing efficiency and purity at all target sites and significantly reduced frequency of chromosomal translocations compared to the conventional CRISPR-Cas9 system. Site-specific knock-in of a chimeric antigen receptor (CAR) and multiplex gene knockout are achieved within a single intervention and without the requirement for additional sequence-targeting components. The ability to perform complex genome editing efficiently and precisely highlights the potential of the Pin-point platform for application in a range of advanced cell therapies.

[1]  H. Volk,et al.  Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells , 2022, bioRxiv.

[2]  T. Severson,et al.  Double-strand break toxicity is chromatin context independent , 2022, Nucleic acids research.

[3]  Katie Kingwell.  Base editors hit the clinic , 2022, Nature Reviews Drug Discovery.

[4]  A. Madi,et al.  Frequent Aneuploidy in Primary Human T Cells after CRISPR-Cas9 cleavage , 2022, Nature biotechnology.

[5]  Jason M. Gehrke,et al.  Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL , 2022, Blood.

[6]  F. Herbst,et al.  Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing , 2022, Molecular cancer.

[7]  R. Jaenisch,et al.  Whole chromosome loss and genomic instability in mouse embryos after CRISPR-Cas9 genome editing , 2021, Nature Communications.

[8]  D. Cappellen,et al.  CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells , 2021, Nature Communications.

[9]  Walker S. Lahr,et al.  CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells , 2021, Nature Communications.

[10]  Ceri M. Wiggins,et al.  Development and Characterization of a Modular CRISPR and RNA Aptamer Mediated Base Editing System. , 2021, The CRISPR journal.

[11]  F. Rahbarizadeh,et al.  CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells , 2021, BMC Biotechnology.

[12]  Matthew J. Frigault,et al.  Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies , 2020, The Lancet.

[13]  W. Qasim,et al.  Base-edited CAR T cells for combinational therapy against T cell malignancies , 2020, bioRxiv.

[14]  Cheng-Zhong Zhang,et al.  Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing , 2020, Nature Genetics.

[15]  S. Tsang,et al.  Allele-Specific Chromosome Removal after Cas9 Cleavage in Human Embryos , 2020, Cell.

[16]  Ruochi Zhang,et al.  CHANGE-seq reveals genetic and epigenetic effects on CRISPR-Cas9 genome-wide activity , 2020, Nature Biotechnology.

[17]  K. Niakan,et al.  Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos , 2020, Proceedings of the National Academy of Sciences.

[18]  Chun Jimmie Ye,et al.  Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies , 2020, Cell.

[19]  Jonathan Yen,et al.  Directed evolution of adenine base editors with increased activity and therapeutic application , 2020, Nature Biotechnology.

[20]  Howard Y. Chang,et al.  CRISPR-engineered T cells in patients with refractory cancer , 2020, Science.

[21]  Martin J. Aryee,et al.  CRISPR DNA base editors with reduced RNA off-target and self-editing activities , 2019, Nature Biotechnology.

[22]  Hui Yang,et al.  Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis , 2019, Nature.

[23]  Martin J. Aryee,et al.  Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors , 2019, Nature.

[24]  R. Pecori,et al.  RNA Editors, Cofactors, and mRNA Targets: An Overview of the C-to-U RNA Editing Machinery and Its Implication in Human Disease , 2018, Genes.

[25]  Klaus N. Lovendahl,et al.  Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors , 2018, Nature Communications.

[26]  Farlan S Veraitch,et al.  A guide to manufacturing CAR T cell therapies. , 2018, Current opinion in biotechnology.

[27]  R. Medema,et al.  A limited number of double-strand DNA breaks is sufficient to delay cell cycle progression , 2018, bioRxiv.

[28]  Mauricio O. Carneiro,et al.  Scaling accurate genetic variant discovery to tens of thousands of samples , 2017, bioRxiv.

[29]  Nicole M. Gaudelli,et al.  Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage , 2017, Nature.

[30]  P. Billon,et al.  CRISPR-Mediated Base Editing Enables Efficient Disruption of Eukaryotic Genes through Induction of STOP Codons. , 2017, Molecular cell.

[31]  Mazhar Adli,et al.  CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations , 2017, Nature Methods.

[32]  J. Joung,et al.  CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets , 2017, Nature Methods.

[33]  Mithat Gönen,et al.  Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection , 2017, Nature.

[34]  David R. Liu,et al.  Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage , 2016, Nature.

[35]  Laurie D. Smith,et al.  A 26-hour system of highly sensitive whole genome sequencing for emergency management of genetic diseases , 2015, Genome Medicine.

[36]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[37]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[38]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[39]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[40]  S. Salzberg,et al.  FLASH: fast length adjustment of short reads to improve genome assemblies , 2022 .

[41]  T. Honjo,et al.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. , 1996, International immunology.

[42]  J. Saiz,et al.  Right‐sided non‐recurrent laryngeal nerve without any vascular anomaly: an anatomical trap , 2021, ANZ journal of surgery.

[43]  I. Weissman,et al.  Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy , 2017, Nature Immunology.